A high pretreatment plasma oestradiol level is associated with a low risk of acute myocardial infarction in parenteral oestrogen therapy for locally advanced prostate cancer

OBJECTIVE To evaluate the relationship of pretreatment plasma oestradiol (ppE2) and testosterone (ppT) level to acute myocardial infarction (AMI) in patients with locally advanced prostate cancer primarily treated with parenteral polyoestradiol phosphate (PEP) or orchidectomy, considering the effect...

Full description

Saved in:
Bibliographic Details
Published in:BJU international 2008-05, Vol.101 (9), p.1090-1095
Main Authors: Mikkola, Arto K.K., Aro, Jussi L.V., Rannikko, A.S. Sakari, Ruutu, Mirja L.
Format: Article
Language:English
Subjects:
Aged
androgen deprivation
Antineoplastic Agents - therapeutic use
Biological and medical sciences
Cardiology. Vascular system
cardiovascular
complications
Coronary heart disease
Estradiol - analogs & derivatives
Estradiol - blood
Estradiol - therapeutic use
Follow-Up Studies
Heart
Humans
Infusions, Parenteral
Male
Medical sciences
Middle Aged
Myocardial Infarction - etiology
Myocardial Infarction - prevention & control
Nephrology. Urinary tract diseases
orchidectomy
Orchiectomy - methods
polyoestradiol phosphate
Prostatic Neoplasms - therapy
Risk Factors
Testosterone - blood
therapy
Treatment Outcome
Tumors of the urinary system
Urinary tract. Prostate gland
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:OBJECTIVE To evaluate the relationship of pretreatment plasma oestradiol (ppE2) and testosterone (ppT) level to acute myocardial infarction (AMI) in patients with locally advanced prostate cancer primarily treated with parenteral polyoestradiol phosphate (PEP) or orchidectomy, considering the effect of age, performance status, pretreatment diseases and medication, and tumour stage and grade. PATIENTS AND METHODS The present Finnprostate 6 study comprised 234 patients randomized to oestradiol or intramuscularly administered PEP (240 mg/month) therapy. Each patient was followed until the end of the primary therapy (up to 10 years) or until the first AMI (lethal or not). RESULTS The risk of AMI, when the PEP and orchidectomy groups were analysed together, was lower in patients with a high ppE2 level, and this risk was independent of the ppT level, pretreatment diseases, medication, age, performance status, disease stage or grade. In the PEP therapy group the risk of AMI was statistically significantly lower in patients with a high ppE2 level (≥93 pmol/L) than in those with a low ppE2 level (
ISSN:1464-4096
1464-410X
DOI:10.1111/j.1464-410X.2007.07361.x